Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (24617)	8/17/1998 11:49:00 AM
From: tony	Respond to of 32384

Bob, LGND has not hit the bottom. It will go to atleast 7 based on market and share dilution. So, all the best to you.

To: bob zagorin who wrote (24617)	8/17/1998 11:49:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

As far as the AGN overhang is concerned, it is my understanding that AGN had 3.4 million shares of LGND. I believe that they sold 1.1 million in 2Q. Recently (about 1 1/2 weeks ago), there was a high volume trading day (over 600K) which included some large blocks (40K to 60K) going off at the bid price (there were more blocks in that range going off at the ask price and the price range of these large blocks was tight, I believe that all went off between 9 7/8 and 10). Since then I have only seen two large blocks in that size range. One was the next day at 10 1/32 and the other was today at 8 11/12.

To: bob zagorin who wrote (24617)	8/17/1998 12:47:00 PM
From: Mudcat	Respond to of 32384

<caveats. 1. overall market conditions 2. AGN stock overhang 3. dilution> Bob, you forgot about Fallaron and the fact that Lgnd will soon be out of cash because thay wasted our money on SRGN.

To: bob zagorin who wrote (24617)	8/17/1998 8:34:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

bob, I still haven't heard from IR, but did get an E-Mail from someone who did get through and I was told that if things go as planned, there will not be a follow on. Some dilution from deals, options, or warrants exercised, but not from a secondary. Sounds like the 10-K had nothing new in spite of the naysayers' many posts. Situation is similar to the FDA letter: Message 4920521 which some interpreted as a rejection (after a 14-0 vote to approve from the advisory committee!!!): messages.yahoo.com@m2.yahoo.com I guess what's most remarkable is the fact that some seem to believe this nonsense.

To: bob zagorin who wrote (24617)	8/17/1998 8:48:00 PM
From: tonyt	Respond to of 32384

NEW YORK, Aug 17 (Reuters) - The following companies reported the greatest deviations above or below analysts' mean estimates. Earnings surprise data provided by Zacks Investment Research. Company Ticker Actual Cons Surp. EPS Est. % ENERGY SEARCH (NASDAQ:EGAS) 0.01 $0.02 150 DEPOTECH CORP (NASDAQ:DEPO) -0.38 $0.52 27 TITAN PHARMA (NASDAQ:TTNP) -0.17 $0.21 19 JINPAN INTL LTD (AMEX:JST) 0.32 $0.28 14 TIFFANY & CO (NYSE:TIF) 0.37 $0.34 9 GLOBAL-TECH (NYSE:GAI) 0.27 $0.25 8 RESMED INC (NASDAQ:RESM) 0.40 $0.37 8 ENERGY BIOSYS (NASDAQ:ENBC) -0.24 $0.26 8 RAVEN INDS INC (NASDAQ:RAVN) 0.31 $0.32 -3 LIGAND PHARMA-B (NASDAQ:LGND) -0.45 $0.35 -29 ASTEA INTL INC (NASDAQ:ATEA) -0.13 $0.10 -30 TECH CHEM&PRODS (NASDAQ:TCPI) -0.26 $0.19 -37 TOP SOURCE TECH (AMEX:TPS) -0.04 $0.02 -100 Copyright 1998, Reuters News Service